PBYI - Puma Biotechnology Inc

PBYI valuation $6.47 billion

Stock Price

Change: ↓ -4.99 (-2.3094%)
Last Update: 2015-01-30T16:17:21-05:00
Shares Outstanding: 30,644,420
Industry: Biotechnology

Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer.

The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use.

The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2-positive breast cancer and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation.

Stock Price Data

Open: 213.87 Previous Close: 216.07
High: 219.29 Low: 210.36
Bid: 211.40 Ask: 299.99

Bid Size: 100 Ask Size: 100
Raw Bid Size: 1 Raw Ask Size: 1
Trade Volume: 2590 Share Volume: 239709
Last Trade Date: 2015-01-30 Last Trade Time: 16:17:02-05:00
Vwap: 215.837493 EPS: -3.71

Fundamental Data

PE ratio: PB ratio: 44.911
Beta: -2.148993

52 Week High: 279.37 52 Week Low: 53.63
52 Week High Vwap: 273.5834 52 Week Low Vwap: 55.0158
52 Week High Volume: 2456760 52 Week Low Volume: 57632
52 Week Avg Volume: 367864
* Quotes delayed 15 minutes

Related Stocks

StockCompany namePrice
GILD Gilead Sciences Inc. 104.83
IMGN ImmunoGen Inc. 7.63
CELG Celgene Corporation 119.16
ARNA Arena Pharmaceuticals Inc. 4.31
MNKD MannKind Corporation 6.35
AMGN Amgen Inc 152.26
NVAX Novavax Inc. 7.81
BIIB Biogen Idec Inc. 389.16
NPSP NPS Pharmaceuticals Inc. 45.86
ARIA ARIAD Pharmaceuticals Inc. 6.45